Xenon Pharmaceuticals Announces Closing of its $60.0 Million Public Offering of Common Shares

Jan 30 17:01 2020 Print This Article

Xenon Pharmaceuticals Announces Closing of its $60.0 Million Public Offering of Common Shares

Original press release here

BURNABY, British Columbia, Jan. 27, 2020 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc.(Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the closing of its previously announced public offering of 3,750,000 common shares pursuant to its existing shelf registration statement at a public offering price of $16.00 per share. The gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Xenon, were $60.0 million. In addition, Xenon has granted to the underwriters of the offering an option for a period of 30 days from January 22, 2020 to purchase up to an additional 562,500 common shares at the public offering price, less the underwriting discounts and commissions.

Read More

About Article Author

Cross Border Biotech Blog

Bloom Burton & Co. is Canada's leading biotechnology and healthcare-specialized investment banking firm, which exists to accelerate returns in healthcare. Bloom Burton has an experienced team of medical, scientific, pharmaceutical, legal and capital markets professionals who perform a deeper level of diligence, which combined with a creative and entrepreneurial approach, leads to the right monetization events for companies and investors. Bloom Burton provides capital raising, M&A advisory, equity research, management consulting, direct investments through equity and debt funds, and company creation services.

Related Items

Market Update: Investors Optimistic as Global Economies Reopen

The quickest bear market in the history of the US S&P 500 turned into the best 50-day bull market rally in history in May. By market close on June 3, 2020, the S&P 500 Index was up 37.7% from its March 23, 2020 low. This bullish investor sentiment has been based on the continued decline in new coro ...

“E” vs “SG” in ethical investing: how sustainable is mollification-by-cherrypicking

In the great game of whack-a-mole that is capital raising in Canada’s oil patch, it must be frustrating, for those whose full-time job when there isn’t a global pandemic is whacking the moles of ESG criteria on which they feel their companies may be vulnerable to criticism and hence subject to ...

Did wind-generated electricity displace gas-generated electricity in Ontario in June 2019?

Financiers of green energy projects often claim in public filings that the energy generated by the projects they have financed has avoided some definite number of tons of CO2 emissions. Run the numbers, and you usually find they have assumed some annual capacity factor, say 35 percent in the case o ...

A deep retrofit of homes and buildings is the megaproject Canada needs

Ramping down carbon emissions from homes and buildings can help us rebuild Canada’s economy after the pandemic. ...

Rebuilding Canada’s economy includes energy resiliency in remote communities (blog)

This is the moment to create a roadmap for a society that is more resilient to these macro shocks – whether they are brought about by a pandemic or climate change. Canada’s response must support a more resilient, healthier economy that is competitive and shows economic strength in a decarbonize ...

BRC Webinar Series

Join the Business Renewables Centre-Canada and some of our founding members for our inaugural BRC Webinar Series to learn about the basics of corporate renewable procurement and what its future in Canada looks like. ...

Customer Success: Formulary Management

In response to customer requests, we’ve built some new tools for formulary management. You can preview these tools at: Recent Generic Drug Launches Upcoming 180-Day Patent Challenge Exclusivity Expirations Anticipate… The post Customer Success: Formulary Management appeared first on DrugPatentW ...

Ottawa postpones short-sighted drug-pricing regulations

Author: Bacchus Barua Planned changes would likely result in fewer new and innovative drugs available to Canadians. Read more about Ottawa postpones short-sighted drug-pricing regulations Tags:  pmprb pharmaceutical drugs pharmaceutical innovation prescription drug prices ...

There’s still upside to Aurinia Pharma, says Mackie Research

All eyes are on a 2021 launch of voclosporin, lead candidate from drug developer Aurinia Pharmaceuticals (Aurinia Pharma Stock Quote, Chart, News NASDAQ:AUPH), but the stock received a target price trim from analyst André Uddin of Mackie Research on Friday, going from $24.00 to $22.00 per share. V ...

Zymeworks ticks all the boxes for a biopharma investment, Paradigm says

Zymeworks (Zymeworks Stock Quote, Chart, News NYSE:ZYME) has what investors should be looking for in a biopharmaceutical company, according to Paradigm Capital analyst Corey Hammill, namely, a strong balance sheet and a healthy-looking pipeline. The analyst reviewed Zymeworks latest quarterly resul ...

Q4 2019 Share Price Performance

Q4 2019 Share Price Performance Healthcare Stocks Surge  In this blog post, the Bloom Burton equity research team summarizes the performance of the Canadian healthcare sector during 4Q-2019, and provides commentary on select stock movements and overall market trends.  Inclusion Criteria  Our ana ...

IMV gets price target cut from Raymond James

New clinical results from biopharm company IMV (IMV Stock Quote, Chart, News TSX:IMV) signal a less straightforward path to commercialization than previously assumed, according to Raymond James analyst David Novak, who reviewed the results in an update to clients on Wednesday. Dartmouth, Nova Scoti ...